Endoscopic radiofrequency ablation of cholangiocarcinoma: new palliative treatment modality (with videos)

Monga, Amitabh; Gupta, Rajesh; Ramchandani, Mohan; Rao, Guduru Venkat; Darisetty, Santosh; Reddy, D. Nageshwar

doi:10.1016/j.gie.2010.10.018

Cited by 55 publications

(39 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…1 previous report asserted that ablation treatment should be performed cautiously because of excessive charring leading to perforation [10]. The intraductal RFA can destroy the tumor tissue to some extent to enlarge the lumen for stent placement, leading to blood vessel loss; this was reported by Monga et al [22]. Our study also presented acceptable complications of RFA-stent in the treatment of selected patients in this study.…”

Section: Discussionsupporting

confidence: 73%

Percutaneous Intraductal Radiofrequency Ablation for Malignant Biliary Obstruction Caused by Recurrence and Metastasis after Primary Tumor Resection

Cui

Fan²,

Lu³

et al. 2018

Oncol Res Treat

View full text Add to dashboard Cite

Background: To assess the feasibility and safety of percutaneous intraductal radiofrequency ablation (RFA) for malignant biliary obstruction caused by recurrence and metastasis after primary tumor resection. Patients and Methods: Percutaneous intraductal biliary RFA and stent placement were performed in 19 consecutive patients with 24 RFA procedures. Procedure-related complications, stent patency, and survival after treatment were investigated. Results: During 30 days after each RFA procedure there was no 30-day mortality, hemorrhage, bile duct perforation, or pancreatitis. Of the 19 patients, 2 are still alive and 17 are dead with a median survival time of 6.0 (range 1.2-16) months and a median stent patency of 3.2 (range 1.2-14) months. 10 patients had their stent patent at the time of last follow-up or death. 3 patients with stent blockage at 50, 182, and 200 days post procedure underwent repeat ablation. 1 patient with stent blockage underwent 2 repeat RFA procedures at 192 days after the first ablation and at 86 days after the repeat ablation. Conclusion: Percutaneous intraductal RFA is a technically safe and feasible therapeutic option for palliative treatment of these selected patients.

show abstract

Section: Discussionsupporting

confidence: 73%

Percutaneous Intraductal Radiofrequency Ablation for Malignant Biliary Obstruction Caused by Recurrence and Metastasis after Primary Tumor Resection

Cui

Fan²,

Lu³

et al. 2018

Oncol Res Treat

View full text Add to dashboard Cite

show abstract

“…58 Recently, we also demonstrated successful ablation of cholangiocarcinoma using radiofrequency ablation. 48 Lu XL et al have also used brachytherapy to ablate a mucin producing bile duct tumor which was confirmed using POC.…”

Section: Palliative Treatment Of Malignant Obstructive Jaundicementioning

confidence: 94%

“…POC has also been reported to be useful in isolated case reports in determination of the source of bleeding in hemobilia 45 , evaluation of recurrent pancreatitis 46 , diagnosis and ablation of biliary neoplasm 41,47,48 and diagnosis of recurrent bile duct stones post cholecystectomy. 49 …”

Section: Other Rare Diagnostic Applicationsmentioning

confidence: 99%

Per-oral cholangioscopy

Monga

Ramchandani²,

Reddy³

2011

jig

Self Cite

View full text Add to dashboard Cite

Direct endoscopic views of bile duct have been described in literature since the 1970s. Since then rapid strides have been made with the advent of technologically advanced systems with better image quality and maneuverability. The single operator semi-disposable per-oral cholangioscope and other novel methods such as the cholangioscopy access balloon are likely to revolutionize this field. Even though cholangioscopy is currently used primarily for characterization of indeterminate strictures and management of large bile duct stones, the diagnostic and therapeutic indications are likely to expand in future. The following is an overview of the currently available per-oral cholangioscopy equipments, indications for use and future directions.

show abstract

“…Monga et al [58] reported a clinical case report of successful therapy of intraductal CCA, while Steel et al [59] reported the feasibility of using intraductal therapy for malignancy, of which only six of 21 cases were diagnosed as CCA. Therefore, more information regarded the efficacy and safety of this particular therapy is still needed; however, it was considered a potential "new tool" for the endobiliary treatment of hilar CCA.…”

Section: Radiofrequency Ablation (Rfa)mentioning

confidence: 99%

Current Status of Endoscopic Treatment of Advanced Hilar Cholangiocarcinoma

Prachayakul¹

2014

J Gastroint Dig Syst

View full text Add to dashboard Cite

Cholangiocarcinoma is a high-mortality primary hepatic malignancy. A higher incidence of cholangiocarcinoma was reported in Asia, especially Southeast Asia, than in Western countries. Hilar cholangiocarcinoma is a specific type of extrahepatic cholangiocarcinoma that involves the hepatic hilum and has a worse prognosis. More than half of the patients with jaundice are inoperable at the time of first diagnosis. Therefore, biliary drainage is the mainstay of palliative treatment in these patients. Endoscopic biliary drainage via endoscopic retrograde cholangiopancreatography, the modality of choice, for the advanced hilar type is more difficult and complex than those in distal cholangiocarcinoma. Endoscopists should consider many factors before selecting the most appropriate treatment for each patient. Here we discuss the factors systematically. In cases of transpapillary approach failure, other therapeutic modalities should be considered. Percutaneous transhepatic biliary drainage is the most popular method in such cases. At the present, endoscopic ultrasound-guided biliary drainage, especially hepaticogastrostomy, is an alternative procedure with the same efficacy and low complications when it was carried out in the expert hands. Furthermore, recent locoregional therapies for tumor control including trans-luminal photodynamic therapy and radiofrequency ablation also benefit these patients.

show abstract

Endoscopic radiofrequency ablation of cholangiocarcinoma: new palliative treatment modality (with videos)

Cited by 55 publications

References 5 publications

Percutaneous Intraductal Radiofrequency Ablation for Malignant Biliary Obstruction Caused by Recurrence and Metastasis after Primary Tumor Resection

Percutaneous Intraductal Radiofrequency Ablation for Malignant Biliary Obstruction Caused by Recurrence and Metastasis after Primary Tumor Resection

Per-oral cholangioscopy

Current Status of Endoscopic Treatment of Advanced Hilar Cholangiocarcinoma

Contact Info

Product

Resources

About